

## PERSONALIZED MEDICINE BY THE NUMBERS

Prominent examples of personalized medicine drugs, treatments and diagnostics products available

**2006**<sup>1</sup> **2014**<sup>2</sup>

13

113

- **30%** of all treatments in late clinical development rely on biomarker data<sup>6</sup>
- 50% of all treatments in early clinical development rely on biomarker data<sup>6</sup>
- 60% of all treatments in preclinical development rely on biomarker data<sup>6</sup>

**30%** of all biopharmaceutical companies surveyed require all compounds in development to have a biomarker<sup>7</sup>

50% of all clinical trials

collect DNA from patients to aid in biomarker development<sup>7</sup>

**75%** increase in personalized medicine investment by industry from 2006-2011<sup>6</sup>

**34%** reduction in chemotherapy use would occur if women with breast cancer receive a genetic test of their tumor prior to treatment<sup>8</sup>

**17,000** strokes could be prevented each year if a genetic test is used to properly dose the blood thinner warfarin<sup>9</sup>

**\$604,000,000** in annual health care cost savings would be realized if patients with metastatic colorectal cancer receive a genetic test for the KRAS gene prior to treatment<sup>10</sup>

Cost of sequencing a human genome

2001<sup>2</sup> 2014<sup>2</sup> \$300,000,000 \$1,000 \tag{

U.S. physicians using electronic records

<b>2006</b> <sup>3</sup>	20134
29%	93% •
using an electronic	reported actively
health system	using electronic
	medical records

**137** FDA-approved drugs have pharmacogenomic information in their labeling<sup>5</sup>

155 pharmacogenomic biomarkers are included on FDA-approved drug label<sup>5</sup>

## Members of the Personalized Medicine Coalition<sup>11</sup>

2004 2014

## REFERENCES

- 1 Personalized Medicine Coalition. The Case for Personalized Medicine. 2011.
- 2 Personalized Medicine Coalition. The Case for Personalized Medicine. 2014.
- Hsiao CJ, Hing E. Use and characteristics of electronic health record systems among office-based physician practices: United States, 2001–2013. NCHS data brief no. 143. Hyattsville, MD: US Department of Health and Human Services, CDC; 2014. Available at http://www.cdc.gov/nchs/data/databriefs/db143.pdf.
- 4 http://newsroom.accenture.com/news/emr-and-hie-use-increases-among-us-doctors-accenture-annual-survey-finds.htm.
- 5 U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. FDA web site. (Available at http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm).
- 6 Tufts Center for the Study of Drug Development. Personalized Medicine Is Playing a Growing Role in Development Pipelines. *Impact Report*, 12 (November/December 2010): 6.
- Tufts Center for the Study of Drug Development. Lack of Clinically Useful Diagnostics Hinder Growth in Personalized Medicines. *Impact Report*, 13 (July/August 2011): 4.
- 8 Genomic Health. Health Economics. Genomic Health web site. (Available at: http://www.genomichealth.com/en-US/Publications/HealthEconomics.aspx#.U446Q5SwK0I).
- 9 McWilliam A, Lutter R, Nardinelli C. AEI-Brookings Joint Center for Regulatory Studies Health Care Savings from Personalizing Medicine Using Genetic Testing: The Case of Warfarin. 2006 AEI-Brookings Joint Center; AEI-Brookings Joint Center for Regulatory Studies 2006.
- 10 Shankaran V. Conference presentation at the Gastrointestinal Cancers Symposium. January 2009. Medscape web site. (Available at: http://www.medscape.com/viewarticle/586946).
- 11 Personalized Medicine Coalition. PMC Membership. PMC web site. (Available at: http://www.personalizedmedicinecoalition.org/).

